Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]

Company Overview - IQVIA Holdings Inc. has a market cap of $32.2 billion and is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry [1] - The company operates through four segments: Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions, and Contract Sales & Medical Solutions [1] Market Position and Growth Potential - IQVIA is classified as a "large-cap" stock and is positioned for steady growth due to its diverse offerings and strong backlog, with digital health and AI trends providing long-term tailwinds [2] - The company has a consensus rating of "Strong Buy" from 22 analysts, with a mean price target of $213.52, indicating a potential upside of 16.1% from current market prices [6] Stock Performance - Shares of IQVIA have decreased 25.9% from their 52-week high of $248.03, but have surged 15.1% over the past three months, outperforming the Langar Global Healthtech ETF's (LGHT) 1.3% decrease [3] - Year-to-date, IQVIA's stock has declined 6.4%, lagging behind LGHT's marginal rise, and over the past 52 weeks, shares have plunged nearly 21.8%, compared to LGHT's 2.3% drop [4] Recent Financial Results - On July 22, IQVIA shares jumped 17.9% following the release of Q2 results, with adjusted EPS of $2.81 exceeding Wall Street's estimate of $2.76, and revenue of $4.02 billion surpassing expectations of $3.96 billion [5] - The company guided for full-year adjusted EPS between $11.75 and $12.05 and revenue in the range of $16.1 to $16.3 billion [5] Competitive Landscape - Top rival Agilent Technologies, Inc. has seen its shares fall 7.6% year-to-date and 10.1% over the past 52 weeks, which is a greater decline than IQVIA's performance during the same timeframe [6]